NASDAQ:IMAB
I-Mab Stock News
$1.58
-0.0400 (-2.47%)
At Close: Jul 02, 2024
I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastri
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
05:05pm, Thursday, 23'rd May 2024
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization o
I-Mab to Participate at the Jefferies Global Healthcare Conference
07:00am, Wednesday, 22'nd May 2024
ROCKVILLE, Md. , May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated
I-MAB Filed 2023 Annual Report on Form 20-F
07:00am, Tuesday, 30'th Apr 2024
ROCKVILLE, Md. , April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
07:00am, Friday, 05'th Apr 2024
ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiat
I-Mab Announces Closing of the Divestiture of Business Operations in China
04:01pm, Tuesday, 02'nd Apr 2024
ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of hig
I-Mab Reports Full Year 2023 Financial Results and Business Update
05:00pm, Thursday, 14'th Mar 2024
Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 Uliledlimab (
I-Mab: Trading Below Net Cash With Multiple Upside Options
03:28am, Sunday, 18'th Feb 2024
I-Mab Biopharma has signed an agreement to divest its assets and business operations in China, becoming a US-based biotech company. The divesting will provide I-Mab with a healthy balance sheet, over
Biotech firm I-Mab to divest China operations, shift focus to US
08:36am, Wednesday, 07'th Feb 2024
I-Mab said on Wednesday it has agreed to divest its operations and assets in China as part of its strategy to become a U.S.-focused biotech firm, sending the company's shares up nearly 11% in premarke
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
06:00am, Wednesday, 07'th Feb 2024
Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncol
I-Mab Announces Participation at Jefferies and Piper Conferences in November
08:00am, Monday, 06'th Nov 2023
ROCKVILLE, Md. and SHANGHAI, China , Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
08:00am, Thursday, 02'nd Nov 2023
FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data from M-PLACE, a Phase 2 study led by I-Mab partner HI-Bio I-Mab has full development and commercializati
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
08:00am, Wednesday, 01'st Nov 2023
ROCKVILLE, MD, U.S. and SHANGHAI, China , Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patie
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
08:00am, Monday, 16'th Oct 2023
ROCKVILLE, Md. and SHANGHAI, China , Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
08:00am, Tuesday, 10'th Oct 2023
- Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose